| Standard treatment group (n = 50) | Anti-TNF group (n = 41) | Group differences | p-values |
---|---|---|---|---|
Age (year): mean (S.D.) | 11.8 (2.0) | 13.8 (2.4) | Z = −3.79 | <0.001 |
Gender (male) | 9 (18.0%) | 12 (29.3%) | χ2(1) = 1.04 | 0.31 |
JIA subtype: |  |  | χ2(6) = 13.0 | 0.04 |
Systemic arthritis | 5 (10.0%) | 9 (22.0%) | Â | Â |
Oligoarthritis persistent | 11 (22.0%) | 1 (2.4%) | Â | Â |
Oligoarthritis extended | 9 (18.0%) | 9 (22.0%) | Â | Â |
Polyarthritis (RF-negative) | 22 (44.0%) | 17 (41.5%) | Â | Â |
Polyarthritis (RF-positive) | 0 (0.0%) | 1 (2.4%) | Â | Â |
Psoriatic arthritis | 1 (2.0%) | 2 (4.9%) | Â | Â |
Enthesitis-related arthritis | 0 (0.0%) | 2 (4.9%) | Â | Â |
Data on subtype n.a. | 2 (4.0%) | Â | Â | Â |
Disease duration (year): mean (S.D.)a | 5.2 (3.6) | 8.0 (3.6) | Z = −3.23 | 0.001 |
Current use of medication: | Â | Â | Â | Â |
NSAID use: | 41 (82.0%) | 17 (41.5%) | χ2(1) = 14.31 | <0.001 |
Use of other analgesics: | 10 (20.0%) | 15 (36.6%) | χ2(1) = 2.33 | 0.13 |
Methotrexate use: | 18 (36.0%) | 17 (41.5%) | χ2(1) = 0.10 | 0.75 |
Anti-TNF agents use: | Â | Â | Â | Â |
Etanercept | Â | 31 (75.6%) | Â | Â |
Adalimumbab | Â | 3 (7.3%) | Â | Â |
Infliximab | Â | 3 (7.3%) | Â | Â |
Treatment time with anti-TNF agents (year) | Â | 2.4 (1.8) | Â | Â |